Expert survey on systemic therapy indications for hepatocellular carcinoma in Korea: bridging clinical practice and reimbursement criteria

• Published in: Journal of liver cancer pp. 160 - 168
• Main Authors: Yang, Hyun, Kim, Soon Sun, Kang, Seong Hee, Kwon, Jieun, Kim, Do Young, Kim, Eunju, Shin, Hyun Phil, Yu, Jeong Il, Yoo, Jeong-Ju, Yoon, Eileen L., Lee, Sangheun, Chon, Young Eun, Jung, Janghan, Cheon, Jaekyung, Choi, Woosun, Han, Seul Ki, Han, Ji Eun, Hur, Moon Haeng, Lee, Hyun Woong, Kim, Hyung Joon
• Format: Journal Article
• Language: English
• Published: Korea (South) 대한간암학회 07.07.2025
• Subjects: 의학일반; Systemic therapy; Hepatocellular carcinoma; Portal vein invasion; Reimbursement criteria; TACE refractoriness
• ISSN: 2288-8128; 2383-5001; 2383-5001
• DOI: 10.17998/jlc.2025.07.02

This survey aimed to collect expert opinions from multidisciplinary specialists involved in the management of hepatocellular carcinoma (HCC) in Korea regarding real-world criteria for systemic therapy indications. In response to discrepancies between national reimbursement policies and clinical decision-making, members of the Korean Liver Cancer Association and Korean Association for the Study of the Liver participated in a web-based survey from February 4 to 14, 2025. A total of 89 respondents, primarily experienced clinicians, provided their views on major clinical scenarios including infiltrative HCC, bilobar multifocal disease, huge tumors, vascular invasion, extrahepatic metastasis, and transarterial chemoembolization (TACE) refractoriness. There was high agreement for including infiltrative HCC (69.7%), suspected portal vein invasion (70.8%), and TACE refractoriness (82.0%) as systemic therapy indications. TACE refractoriness, in particular, aligns with current guideline definitions. Additionally, over half of respondents (51.7%) supported extrahepatic metastasis under similar conditions. Notably, multidisciplinary discussion was emphasized across scenarios, but many respondents also favored allowing primary physician discretion in select cases. This report provides consolidated expert input to inform future updates to reimbursement policies and promote alignment with real-world clinical practice. These findings may help bridge the gap between national coverage criteria and clinical decision in systemic therapy for HCC.